OBJECTIVES: The development of oral squamous cell carcinoma (OSCC) is a complex, multistep process. To date, numerous oncogenes and tumor-suppressor genes have been implicated in oral carcinogenesis. Of particular interest in this regard are genes involved in cell cycling and apoptosis, such BRAF, KRAS, and PIK3CA genes. STUDY DESIGN: Mutations of BRAF, KRAS, and PIK3CA were evaluated by direct genomic sequencing of exons 1 of KRAS, 11 and 15 of BRAF, and 9 and 20 of PIK3CA in OSCC specimens. RESULTS: Both BRAF and KRAS mutations were detected with a mutation frequency of 2% (1/42). PIK3CA mutations were detected at 3% (1/35). CONCLUSIONS: This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.
OBJECTIVES: The development of oral squamous cell carcinoma (OSCC) is a complex, multistep process. To date, numerous oncogenes and tumor-suppressor genes have been implicated in oral carcinogenesis. Of particular interest in this regard are genes involved in cell cycling and apoptosis, such BRAF, KRAS, and PIK3CA genes. STUDY DESIGN: Mutations of BRAF, KRAS, and PIK3CA were evaluated by direct genomic sequencing of exons 1 of KRAS, 11 and 15 of BRAF, and 9 and 20 of PIK3CA in OSCC specimens. RESULTS: Both BRAF and KRAS mutations were detected with a mutation frequency of 2% (1/42). PIK3CA mutations were detected at 3% (1/35). CONCLUSIONS: This is the first report implicating BRAF mutation in OSCC. Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.
Authors: Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu Journal: Science Date: 2004-03-11 Impact factor: 47.728
Authors: D Saranath; S E Chang; L T Bhoite; R G Panchal; I B Kerr; A R Mehta; N W Johnson; M G Deo Journal: Br J Cancer Date: 1991-04 Impact factor: 7.640
Authors: Darío García-Carracedo; Yi Cai; Wanglong Qiu; Kiyoshi Saeki; Richard A Friedman; Andrew Lee; Yinglu Li; Elizabeth M Goldberg; Elias E Stratikopoulos; Ramon Parsons; Chao Lu; Argiris Efstratiadis; Elizabeth M Philipone; Angela J Yoon; Gloria H Su Journal: Mol Cancer Res Date: 2020-03-09 Impact factor: 5.852
Authors: Louise van der Weyden; Maria P Alcolea; Philip H Jones; Alistair G Rust; Mark J Arends; David J Adams Journal: J Pathol Date: 2011-03-07 Impact factor: 7.996
Authors: Anna Starzyńska; Aleksandra Sejda; Paulina Adamska; Giulia Marvaso; Monika Sakowicz-Burkiewicz; Łukasz Adamski; Barbara A Jereczek-Fossa Journal: Arch Med Sci Date: 2020-11-13 Impact factor: 3.318
Authors: Wanglong Qiu; Guo-Xia Tong; Andrew T Turk; Lanny G Close; Salvatore M Caruana; Gloria H Su Journal: Biomed Res Int Date: 2014-01-08 Impact factor: 3.411